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Background: A variety of different stents and embolic protection devices (EPD) are used for carotid artery stenting (CAS). Little is known about 
current usage patterns and differences in outcomes with these devices.
Methods: We analyzed 9863 consecutive carotid stent procedures in the NCDRR CARER registry performed between January, 2007 and March, 
2011. We compared baseline characteristics and crude and multivariable-adjusted rates of in-hospital combined death/stroke/MI among patients 
treated with Acculink/Accunet, Xact/Emboshield, and Precise/Angioguard stent/EPD combinations.
Results: In 80.1% of cases, stents were used in conjunction with their specific, corresponding FDA-approved EPD. The Acculink/Accunet (n = 2508, 
25.4%), Xact/Emboshield (n = 2460, 24.9%), and Precise/Angioguard (n = 2358, 23.9%) stent/EPD combinations were used in 74.3% of all cases 
with the Protégé/SpiderFx (n = 382, 3.9%) and Wallstent/Filterwire (n=181, 1.9%) devices used in fewer cases. In unadjusted analyses, the Precise/
Angioguard system was associated with a higher rate of the primary outcome than the Acculink/Accunet (3.1% vs. 2.0%, p = 0.02) and Xact/
Emboshield (3.1% vs. 2.3%, p = 0.10) systems. In adjusted analyses, differences between Precise/Angioguard and Accunet/Acculink (OR = 1.64, 
95% CI [0.98-2.76], p=0.02) approached significance. Differences between Precise/Angioguard and Xact/Emboshield (OR = 1.31, 95% CI [0.82-
2.08], p = 0.15) as well as those between Xact/Emboshield and Accunet/Acculink (OR = 1.25, 95% CI [0.76 - 2.05], p = 0.27) were not significant.
Conclusions: In domestic practice, the Acculink/Accunet, Xact/Emboshield, and Precise/Angioguard carotid stenting systems are used in the 
majority of cases with nearly equal frequency. All are associated with low rates of death/stroke/MI. Our analysis showed a trend towards higher 
adverse events with use of the Precise/Angioguard combination when compared to the Acculink/Accunet carotid stenting system. This could be 
attributed to differences in devices or unmeasured confounders such as operator experience/specialty and other unevenly distributed patient-level 
characteristics not captured in this registry.
